IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#879
Positioning
Market Dominance
Manufacturing
Medical Equipment
$7.7B
Joe E. Kiani
Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions. Masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse. monitoring. monitoring to address the primary limitations of conventional pulse Oximetry. It offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals.
Headcount
6.2K
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = MASI ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$MASI MASIMO CORP | 58 | 79 | 68 | 44 | - | 33.6x | -12.1% | -5.4% | 62.5% | 19.9% | -6.6% | -0.1% | 0.0% | 69.0x | $7.7B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
MASIMO CORP (MASI) receives a "Hold" rating with a composite score of 58.1/100. It ranks #879 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Joe E. Kiani
Chief Executive Officer
Labor Force
6,200
79
28
51
Audit Verdict: Average governance indicators based on financial metrics.
No recent insider transactions available for MASI
HQ Base
Wilmington, California
In-line with peers — no strong momentum signal
Trading at a discount to fundamentals — favorable entry valuation
High profitability & efficiency — strong quality floor supports entry
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for MASI.
View All RatingsMaterial decline in asset turnover efficiency detected
High margin volatility — erratic forensic earnings quality
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 79 | 88 | -9DRAG |
| MOMENTUM | 44 | 27 | +17ALPHA |
| VALUATION | 68 | 61 | +7ALPHA |
| INVESTMENT | 28 | 28 | 0NEUTRAL |
| STABILITY | 51 | 37 | +14ALPHA |
| SHORT INT | 41 | 33 | +8ALPHA |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy -12.1% (sector -2.5%)
GM 62% vs sector 43%, OM 20% vs sector 1%
Capital turnover N/A, R&D intensity 8.1%
Rev growth -0%, 11yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our model assigns MASIMO CORP a Hold rating, with a composite score of 58.1/100 and 3 out of 5 stars. Ranked #879 of 7,333 stocks, MASI presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
MASI earns a quality score of 79/100, indicating above-average business quality. The company reports a return on equity of -12.1% (sector avg: -2.5%), gross margins of 62.5% (sector avg: 42.5%), net margins of -6.6% (sector avg: -0.2%). Companies in this tier generally demonstrate consistent profitability and efficient capital deployment, though they may face some competitive pressure.
MASI's value score of 68/100 indicates the stock is fairly valued based on its current fundamentals. Key valuation metrics include an EV/EBITDA of 33.57x, a P/B ratio of 11.61x. At this level, neither a clear bargain nor overpriced, the stock's attractiveness depends more on forward growth expectations and qualitative factors.
MASIMO CORP's investment score of 28/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -0.1% vs. a sector average of 5.9% and a return on assets of -5.4% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
MASI is currently showing below-average momentum at 44/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth stands at -0.1% year-over-year, while a beta of 1.21 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
With a stability score of 51/100, MASI exhibits average financial resilience. Key stability metrics include a beta of 1.21 and a debt-to-equity ratio of 69.00x (sector avg: 0.2x). While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.
The short interest score of 41/100 for MASI suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include above-average market sensitivity (beta: 1.21), elevated leverage (D/E: 69.00x). With a $7.7B market cap (mid-cap), MASIMO CORP may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
MASIMO CORP is a mid-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #879 of 7,333 overall (88th percentile). Key comparisons include ROE of -12.1% trailing the -2.5% sector median and operating margins of 19.9% above the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While MASI currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Key factor gap
Quality (79) vs Investment (28) — closing this gap could shift the rating.
EV/EBITDA 193% ABOVE SECTOR MEDIAN
ROE 389% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 47% ABOVE SECTOR MEDIAN (FAVORABLE)
AUDIT DATA AS OF SEP 27, 2025 (Q2 FY2025)
We rate MASIMO CORP (MASI) as a Hold with a composite score of 58.1/100 at a current price of $175.34. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling for existing holders. Our factors are split, and the overall profile suggests patience is warranted.
The rating is primarily driven by strength in quality (79th percentile) and value (68th percentile), which together account for the majority of the composite score. Offsetting weakness in investment (28th percentile) and momentum (44th percentile) tempers our overall conviction. We assign a No Moat rating (35/100), High uncertainty, and Poor capital allocation.
Key items to watch: the path to profitability. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
MASIMO CORP holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 58.1/100 places it at rank #879 in our full 7,333-stock universe. At $7.7B in market capitalization, MASIMO CORP is a mid-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue contraction of -0% combined with momentum at the 44th percentile paints a cautious picture of the near-term business outlook. The market appears to be pricing in continued challenges, and a catalyst for reversal is not clearly visible from current data.
The margin cascade tells an important story: gross margins of 62% (+20.0pp vs sector) narrow to operating margins of 20% (+18.7pp vs sector) and net margins of -6.6%, yielding a gross-to-net conversion rate of -11%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $175.34, MASIMO CORP is trading near fair value based on current fundamentals. Our value factor score of 68/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. Valuation metrics are mixed, with no strong signal of mispricing in either direction.
The stock currently trades at EV/EBITDA of 33.6x (at a premium), P/B of 11.6x, P/S of 6.3x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Gross margins of 62% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
A value factor score of 68/100 suggests the market is underpricing these fundamentals, creating a potential margin of safety for new investors.
Revenue decline of -0% signals business deterioration — declining revenues make it difficult to grow into the current valuation and often precede further negative revisions.
Thin net margins of -6.6% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
We assign a High uncertainty rating to MASIMO CORP. Key risk factors include current negative profitability (net margin -6.6%), the combination of leverage (69% D/E) and thin margins (-6.6% net) amplifies downside risk. The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: current negative profitability (net margin -6.6%); the combination of leverage (69% D/E) and thin margins (-6.6% net) amplifies downside risk. Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 51th percentile and quality factor at the 79th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 62% provide a buffer against cost pressures. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate MASIMO CORP's capital allocation as Poor. Key concerns include low returns on equity (-12.1%), negative profitability, weak asset returns (ROA -5.4%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — MASIMO CORP significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, MASIMO CORP receives a Hold rating with a composite score of 58.1/100 (rank #879 of 7,333). Our quantitative framework assigns a No Moat (35/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 54/100.
Our analysis supports a neutral stance on MASIMO CORP. While the quantitative profile is not weak enough to warrant selling, it lacks the multi-factor strength required for a buy recommendation. Existing holders should maintain positions and monitor for catalysts — either fundamental improvement or valuation compression — that would shift the risk-reward balance.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign MASIMO CORP a meaningful economic moat, scoring 35/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, margin superiority, reached only 18.1/20.
The strongest moat sources are margin superiority (18.1/20) and financial resilience (7.1/20). GM 62% vs sector 43%, OM 20% vs sector 1%. Interest coverage N/A. These pillars form the core of MASIMO CORP's competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include economic value creation (1.2/20) and reinvestment efficiency (2.8/20). ROE proxy -12.1% (sector -2.5%). Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect MASIMO CORP's moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 62% providing a solid profitability foundation, operating margins of 20% reflecting effective cost management, declining revenues (-0%) that pressure the earnings outlook. The margin cascade from 62% gross to 20% operating to -6.6% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that the profit engine is high-quality and likely sustainable, with the quality factor at the 79th percentile.
The margin profile shows gross margins of 62%, operating margins of 20%, net margins of -6.6%. Return metrics include ROE of -12.1% and ROA of -5.4%. Relative to the Manufacturing sector, gross margins are 20.0 percentage points above the sector median of 43%, and ROE of -12.1% compares to a sector median of -2.5%.
The balance sheet reflects moderate leverage with D/E of 69%, revenue growth of -0%. The sector median D/E is 0%, putting MASIMO CORP at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Above 50MA
37.18%
Net New Highs
+51081
Danaher Corporation (NYSE:DHR) is one of the 10 best life sciences stocks to buy according to hedge funds. On February 17, Danaher Corporation (NYSE:DHR) announced an agreement to acquire Masimo Corporation (NASDAQ:MASI) for nearly $9.9 billion. In the all-cash deal, Danaher will acquire 100% of the common shares outstanding at $180 per share. This translates […]
Danaher Corporation has agreed to acquire Masimo Corporation, positioning Masimo as a standalone business within Danaher's Diagnostics segment. The transaction has been unanimously approved by both companies' boards. Masimo trades on the NasdaqGS under the ticker NasdaqGS:MASI, with a recent share price of $175.25. For you as an investor, this deal connects Masimo, a med tech player, with a large industry buyer that intends to keep it as a focused diagnostics business. The stock has...
Danaher (NYSE:DHR) has entered a definitive agreement to acquire health tech firm Masimo. The deal will bring Masimo into Danaher as a standalone operating unit within its diagnostics-focused portfolio. The transaction is positioned as a material move for Danaher’s presence in patient monitoring and clinical diagnostics. For you as an investor, this deal sits at the intersection of medical technology and diagnostics, two areas that continue to attract attention from large healthcare groups...

Danaher agreed to acquire Masimo Corporation for $180 per share in an all-cash deal valued at $9.9 billion. The acquisition is expected to be accretive to earnings by $0.15-$0.20 in the first full year and approximately $0.70 by the fifth year, with projected annual synergies exceeding $175 million. Analysts view the deal as having sound financial rationale with strong recurring revenue and margin improvement potential.

Danaher Corp. is reportedly nearing a $9.9 billion acquisition of Masimo Corp., with an announcement potentially coming as early as Tuesday. The deal represents a significant premium to Masimo's $7 billion market cap and follows governance changes driven by activist investors. Masimo shares surged 34.51% on the news, while Danaher shares fell 5.22% in premarket trading.